603456.SH
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 15.37
+1.99%Oct 21, 2026, 08:28 UTC
Jiuzhou Pharmaceutical reported first-nine-month 2026 revenue of 3.937 billion yuan, down 5.38% year over year, and attributable net profit of 617 million yuan, down 17.5%.
Source:Oct 21, 2026, 08:28 UTC
Jiuzhou Pharmaceutical reported third-quarter 2026 revenue of 1.361 billion yuan, up 5.58% year over year, and attributable net profit of 229 million yuan, up 3.41%.
Source:Sep 29, 2026, 08:29 UTC
Zhejiang Jiuzhou Pharmaceutical completed a share buyback of 15.4128 million shares, representing 1.75% of total share capital, paying 212 million yuan, of which 6.1651 million shares will be cancelled on September 30, 2026, and the remaining 9.2477 million shares are intended for an employee stock ownership plan or equity incentive.
Source:Sep 3, 2026, 10:16 UTC
Jiuzhou Pharmaceutical's wholly-owned subsidiary Jiuzhou Biomedicine (Taizhou) received drug registration certificates from China's National Medical Products Administration for its buspirone citrate tablets in 5mg and 10mg strengths.
Source:Aug 16, 2026, 13:57 UTC
Jiuzhou Pharmaceutical disclosed that its CDMO business new orders grew steadily in H1 2026, adding 66 early-stage clinical projects, 5 Phase III-to-pre-launch projects, and 5 commercial projects.
Jul 6, 2026, 09:20 UTC
Jiuzhou Pharmaceutical cancels 7.736 million repurchased shares on July 7, reducing total share capital from 889 million to 882 million shares.
Source: